The document provided to this rewrite contained site navigation and the article heading only. It did not include study text, tables, figures, or supplementary material. As a result, the source did not report any specific safety signals, renal outcomes, or adverse-event frequencies related to the regimen of an immune checkpoint inhibitor combined with bevacizumab-based chemotherapy in patients with KRAS-mutant non-squamous NSCLC. Clinicians should treat the absence of data here as a gap requiring retrieval of the complete article for verification.
The title confirms a clear focus: investigators evaluated an immune checkpoint inhibitor plus bevacizumab-based chemotherapy in advanced or recurrent KRAS-mutant non-squamous NSCLC, under the SPIRAL-STONE protocol name. That is the only substantive content available in the supplied material. The source did not provide the study abstract, nor did it list primary or secondary endpoints. The title names the molecular subgroup and the therapeutic agents but offers no information about efficacy, safety, or patient selection.
The supplied content contained no efficacy data. The investigators’ results — objective response rate (ORR), progression-free survival (PFS), overall survival (OS), disease control rate, or duration of response — were not reported in the material provided. The document also lacked any numerical outcomes or comparative analyses. Because those metrics are central to interpreting a combination trial in advanced KRAS-mutant non-squamous NSCLC, their absence prevents readers from evaluating whether the regimen altered clinical outcomes.
Safety information was not available in the provided source text. The supplied material did not include the frequency or severity of treatment-emergent adverse events, the incidence of immune-related adverse events, or specific complications known to be associated with bevacizumab (for example, bleeding, hypertension, or proteinuria). Dose modifications, discontinuation rates, and attribution of events to the immune checkpoint inhibitor versus chemotherapy were likewise not present. This lack of safety detail limits immediate clinical interpretation.
The source did not present core methodological information. Sample size, eligibility criteria, randomization or single-arm status, control arms (if any), treatment cycles, dosing schedules, and duration of follow-up were absent from the provided content. The statistical analysis plan and prespecified primary endpoint—whether efficacy or safety—were not available. Without those elements, reviewers cannot judge internal validity, risk of bias, or the strength of any reported association.
KRAS-mutant lung adenocarcinoma is molecularly heterogeneous. The supplied text did not report whether investigators stratified by KRAS subtype (for example, G12C versus other variants), co-occurring mutations, or tumor PD-L1 expression. No translational or biomarker data were available in the material provided. Those analyses would be important for clinical application but must be sought in the full journal article.
Limitations and next steps based on the supplied material The rewrite above is constrained by the content supplied: only the article title and site navigation were available. The source did not report methods, numerical results, or safety data. Readers and clinicians should retrieve the full Frontiers in Immunology article for complete efficacy, safety, methodological, and biomarker information before drawing clinical conclusions or changing practice. Specific unanswered questions that require the full text include: the trial’s design and endpoints, sample size and baseline demographics, detailed efficacy outcomes (ORR, PFS, OS), comprehensive safety tables including immune-related toxicities, dosing and schedule of each agent, and any subgroup or biomarker analyses reported by the study team.